The effect on lymphocyte subsets of decreasing/stopping tyrosine kinase inhibitor therapy in chronic myeloid leukaemia: data from the DESTINY trial

chronic myeloid leukaemia; imatinib; lymphocyte subsets; treatment discontinuation; tyrosine kinase inhibitors.

浏览次数：49 分享：

Gemma M Austin, Katy Knight, Joanne Bell, Anthony Carter, Earnest Heartin, David Watson, Letizia Foroni, Stephen E Christmas, Fotios Polydoros, Richard E Clark

期刊 Clinical Trial
影响因子 2.2
起止号 2019 May;185(4):791-793.
种属 Human
技术平台流式
应用领域循环系统
研究方向循环系统
细胞类型粒细胞
疾病类型白血病
检测蛋白 CCR7 (CD197),CD127,CD25,CD4,CD45,CD45RA
doi doi: 10.1111/bjh.15629.

Abstract

No abstract availableKeywords: chronic myeloid leukaemia; imatinib; lymphocyte subsets; treatment discontinuation; tyrosine kinase inhibitors.

金课堂之文献解析文献原文请点击

技术文章更多

研究领域更多

热点文献

首页 >

技术资源 >

文献中心 >

Abstract